ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals (NYSE:VRX) today announced that it has signed an agreement with GlaxoSmithKline (NYSE:GSK) for the promotion of Diastat® and Diastat® AcuDial™, the first and only FDA-approved, acute at-home medication for patients two years and older on stable antiepileptic medications (AEDs) who experience bouts of increased seizure activity, sometimes called serial or cluster seizures or breakthrough seizures.
